Press releaseBusiness Wire
Lantern Pharma
LTRN · NASDAQ
$0.6564+$0.0151 (+2.35%)TodayMarket closed ·
Prev close $0.6413
Latest news
- Press releaseBusiness Wire
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
- Press releaseBusiness Wire
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
- Press releaseBusiness Wire
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
- Press releaseBusiness Wire
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
- Press releaseBusiness Wire
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
- News
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
- Press releaseBusiness Wire
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
- Press releaseBusiness Wire
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseBusiness Wire
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
- Press releaseBusiness Wire
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
- Press releaseBusiness Wire
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
- Press releaseBusiness Wire
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
- Press releaseBusiness Wire
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
- Press releaseBusiness Wire
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
- Press releaseBusiness Wire
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseBusiness Wire
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
- News
Earnings Scheduled For May 15, 2026
- Press releaseBusiness Wire
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseBusiness Wire
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
- Press releaseBusiness Wire
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
- Press releaseBusiness Wire
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
- Press releaseBusiness Wire
Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
- Press releaseBusiness Wire
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
- Press releaseBusiness Wire
Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
- Press releaseBusiness Wire
Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
- Press releaseBusiness Wire
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- NewsKaustubh Bagalkote
Why Is Lantern Pharma Stock Soaring Monday?
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.